Dynavax Technologies (DVAX) Slammed on CRL; Is it Now a Bounce Candidate?

February 25, 2013 8:14 AM EST Send to a Friend
Dynavax Technologies Corporation (NASDAQ: DVAX) is down 30 percent to $2.07 following a CRL from the FDA regarding its Biologic License Application (BLA) for HEPLISAV, an investigational adult hepatitis B vaccine. Some, however, are looking for a bounce.

On Friday, analysts at Jefferies said the stock would still be a buy with a CRL. "We have revised our scenarios for Friday’s Heplisav FDA decision and added a scenario in which the company receives a complete response letter and refiles in 2Q13 for chronic kidney disease (CKD) patients," the analyst said. "We estimate that this could be approved by early 2014 and would still yield a $5 valuation. We would be buyers on any weakness if a complete response letter is issued on Friday."


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Momentum Movers, Trader Talk

Related Entities

Jefferies & Co

Add Your Comment